International Journal of Cancer Management

Published by: Kowsar

Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects

Bayazid Ghaderi 1 , Sabrieh Amini 2 , Farzad Maroofi 2 , Chiya Jalali 2 , Mitra Javanmardi 2 , Daem Roshani 3 and Mohammad Abdi 4 , 5 , *
Authors Information
1 Department of Internal Medicine, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
2 Department of Biology, College of Science, Islamic Azad University, Sanandaj, IR Iran
3 Department of Epidemiology and Biostatistics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
4 Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
5 Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: June 2016, 9 (3); e5069
  • Published Online: June 13, 2016
  • Article Type: Research Article
  • Received: December 17, 2015
  • Accepted: May 30, 2016
  • DOI: 10.17795/ijcp-5069

To Cite: Ghaderi B, Amini S, Maroofi F, Jalali C, Javanmardi M, et al. Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects, Int J Cancer Manag. 2016 ; 9(3):e5069. doi: 10.17795/ijcp-5069.

Abstract
Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Everaus H, Luik E, Lehtmaa J. Active and indolent chronic lymphocytic leukaemia--immune and hormonal peculiarities. Cancer Immunol Immunother. 1997; 45(2): 109-14[PubMed]
  • 2. Bartik MM, Welker D, Kay NE. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol. 1998; 25(1): 27-33[PubMed]
  • 3. Bonyhadi M, Frohlich M, Rasmussen A, Ferrand C, Grosmaire L, Robinet E, et al. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol. 2005; 174(4): 2366-75[PubMed]
  • 4. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997; 3(9): 984-9[PubMed]
  • 5. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998; 101(5): 1133-41[DOI][PubMed]
  • 6. Rossi E, Matutes E, Morilla R, Owusu-Ankomah K, Heffernan AM, Catovsky D. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia. 1996; 10(3): 494-7[PubMed]
  • 7. Shih LY, Liang DC. Non-Hodgkin's lymphomas in Asia. Hematol Oncol Clin North Am. 1991; 5(5): 983-1001[PubMed]
  • 8. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998; 9(7): 717-20[PubMed]
  • 9. Kalpadakis C, Pangalis GA, Sachanas S, Vassilakopoulos TP, Kyriakaki S, Korkolopoulou P, et al. New insights into monoclonal B-cell lymphocytosis. Biomed Res Int. 2014; 2014: 258917[DOI][PubMed]
  • 10. Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014; 312(21): 2265-76[DOI][PubMed]
  • 11. Phillis JW. Adenosine and adenine nucleotides as regulators of cellular function. 1991;
  • 12. Conway EJ, Cooke R. The deaminases of adenosine and adenylic acid in blood and tissues. Biochem J. 1939; 33(4): 479-92[PubMed]
  • 13. Van der Weyden MB, Kelley WN. Human adenosine deaminase. Distribution and properties. J Biol Chem. 1976; 251(18): 5448-56[PubMed]
  • 14. Adams A, Harkness RA. Adenosine deaminase activity in thymus and other human tissues. Clin Exp Immunol. 1976; 26(3): 647-9[PubMed]
  • 15. Zidek Z. Adenosine - cyclic AMP pathways and cytokine expression. Eur Cytokine Netw. 1999; 10(3): 319-28[PubMed]
  • 16. Abdi M, Ahmadi A, Roshany D, Khodadadi I, Javid S, Shahmohammad-Nezhad S, et al. Diagnostic value of serum adenosine deaminase activity in HIV infected patients of Kurdish population. Clin Lab. 2013; 59(7-8): 757-62[PubMed]
  • 17. Goodarzi MT, Abdi M, Tavilani H, Nadi E, Rashidi M. Adenosine deaminase activity in COPD patients and healthy subjects. Iran J Allergy Asthma Immunol. 2010; 9(1): 7-12[PubMed]
  • 18. Khodadadi I, Abdi M, Ahmadi A, Wahedi MS, Menbari S, Lahoorpour F, et al. Analysis of serum adenosine deaminase (ADA) and ADA1 and ADA2 isoenzyme activities in HIV positive and HIV-HBV co-infected patients. Clin Biochem. 2011; 44(12): 980-3[DOI][PubMed]
  • 19. Khodadadi I, Vahedi MS, Abdi M, Daneshkhah N, Rahbari R, Menbari S, et al. Evaluation of adenosine deaminase (ADA) isoenzymes activity and tumor necrosis factor-alpha (TNFalpha) concentration in chronic heart failure. EXCLI J. 2014; 13: 58-66[PubMed]
  • 20. Nikkhoo B, Sigari N, Ghaderi B, Afkhamzadeh A, Azadi NA, Mohsenpour B, et al. Diagnostic Utility of Adenosine Deaminase in Serum and Bronchoalveolar Lavage Fluid for Screening Lung Cancer in Western Iran. J Med Biochem. 2013; 32(2): 109-15
  • 21. Urunsak IF, Gulec UK, Paydas S, Seydaoglu G, Guzel AB, Vardar MA. Adenosine deaminase activity in patients with ovarian neoplasms. Arch Gynecol Obstet. 2012; 286(1): 155-9[DOI][PubMed]
  • 22. Buyukberber M, Sevinc A, Cagliyan CE, Gulsen MT, Sari I, Camci C. Non-Hodgkin lymphoma with high adenosine deaminase levels mimicking peritoneal tuberculosis: an unusual presentation. Leuk Lymphoma. 2006; 47(3): 565-8[DOI][PubMed]
  • 23. Mozaheb Z, Aledavood A, Farzad F. Distributions of major sub-types of lymphoid malignancies among adults in Mashhad, Iran. Cancer Epidemiol. 2011; 35(1): 26-9[DOI][PubMed]
  • 24. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46(2): 219-34[PubMed]
  • 25. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006; 107(3): 859-61[DOI][PubMed]
  • 26. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12): 5446-56[DOI][PubMed]
  • 27. Giusti G, Galanti B. Adenosine deaminase. Methods Enzym Analysis. 1974; 2: 1092-9
  • 28. van Laarhoven JP, de Bruyn CH. Purine metabolism in relation to leukemia and lymphoid cell differentiation. Leuk Res. 1983; 7(4): 451-80[PubMed]
  • 29. van Laarhoven JPRM, Spierenburg GT, Collet H, Delespesse G, De Bruyn CHMM. Purine Interconversion Pathways in T, B, Tγ and T-Tγ Cells from Human Peripheral Blood. Adv Exp Med Biol. 1984; 165: 111-8[DOI]
  • 30. Aghaei M, Karami-Tehrani F, Salami S, Atri M. Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors. Arch Med Res. 2010; 41(1): 14-8[DOI][PubMed]
  • 31. Aghaei M, Karami-Tehrani F, Salami S, Atri M. Adenosine deaminase activity in the serum and malignant tumors of breast cancer: the assessment of isoenzyme ADA1 and ADA2 activities. Clin Biochem. 2005; 38(10): 887-91[DOI][PubMed]
  • 32. Eroglu A, Canbolat O, Demirci S, Kocaoglu H, Eryavuz Y, Akgul H. Activities of adenosine deaminase and 5'-nucleotidase in cancerous and noncancerous human colorectal tissues. Med Oncol. 2000; 17(4): 319-24[DOI][PubMed]
  • 33. Urschel JD, Blewett CJ, Bennett WF, Miller JD, Young JE. Handsewn or stapled esophagogastric anastomoses after esophagectomy for cancer: meta-analysis of randomized controlled trials. Dis Esophagus. 2001; 14(3-4): 212-7[PubMed]
  • 34. Yoo C, Yoon DH, Suh C. Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. Blood Res. 2014; 49(3): 148-53[DOI][PubMed]
  • 35. Martin M, Aran JM, Colomer D, Huguet J, Centelles JJ, Vives-Corrons JL, et al. Surface adenosine deaminase. A novel B-cell marker in chronic lymphocytic leukemia. Hum Immunol. 1995; 42(3): 265-73[PubMed]
  • 36. Mesarosova A, Hrivnakova A, Babusikova O. A comparison of some leucocyte differentiation markers and the adenosine deaminase and purine nucleoside phosphorylase values in B and T cell leukemias and lymphomas. Neoplasma. 1995; 42(6): 307-12[PubMed]
  • 37. Yasmineh WG, Brynes RK, Lum CT, Abbasnezhad M. Adenosine deaminase activity in lymphocytes of normal persons, leukemic patients, and kidney-transplant recipients. Clin Chem. 1977; 23(11): 2024-9[PubMed]
  • 38. Simpkins H, Stanton A, Davis BH. Adenosine deaminase activity in lymphoid subpopulations and leukemias. Cancer Res. 1981; 41(8): 3107-10[PubMed]
  • 39. Franco R, Canela EI, Bozal J. Heterogeneous localization of some purine enzymes in subcellular fractions of rat brain and cerebellum. Neurochem Res. 1986; 11(3): 423-35[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments